about
Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosisRegenerative cellular therapies for neurologic diseasesThe ethics of placebo controlled clinical trials in NMO - A balance of risksEnhancing Brain Lesions during Acute Optic Neuritis and/or Longitudinally Extensive Transverse Myelitis May Portend a Higher Relapse Rate in Neuromyelitis Optica Spectrum Disorders.Two-year observational study of deferiprone in superficial siderosis.Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder.MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorderPrevalence and characteristics of transverse myelitis and neuromyelitis optica spectrum disorders in the United Arab Emirates: A multicenter, retrospective studyEffect of CXCR2 Inhibition on Behavioral Outcomes and Pathology in Rat Model of Neuromyelitis OpticaOutcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatmentRadiological characteristics of myelin oligodendrocyte glycoprotein antibody diseaseClinical and radiological characteristics of neuromyelitis optica spectrum disorder in the North Egyptian Nile DeltaCognitive functions in Egyptian neuromyelitis optica spectrum disorderMRI Predictors of Recurrence and Outcome after Acute Transverse Myelitis of Unidentified EtiologyClinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorderTen years of iron chelation in a patient with superficial siderosisReview of Treatment for Central Spinal Neuropathic Pain and Its Effect on Quality of Life: Implications for Neuromyelitis Optica Spectrum DisorderBrain MRI Findings in Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Challenges in Differentiation from Acute Disseminated EncephalomyelitisAquaporin-4 Expression Patterns in Glioblastoma Pre-Chemoradiation and at Time of Suspected ProgressionRisk of Hematoma From Aspirin or Clopidogrel Owing to Lumbar PunctureEffectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disordersMRI differences between MOG antibody disease and AQP4 NMOSDExpanding the spectrum of MOG antibody diseaseReply
P50
Q28647496-E684878F-ECBC-4DEE-B1BC-7F2038C6335FQ36522668-17CBD9D3-32DF-4D70-89C4-689CF96435B7Q36736121-5DE347BE-F5ED-4EB4-8DC7-2CE5CB7BBEE5Q43067194-7D6945F1-354D-4DF2-A1E6-6C67976D03E1Q47235740-CB5E5E33-A951-45F2-BE12-C6DF47DFC828Q54204148-418B1C04-1E07-4771-B756-509B11C9332FQ59747565-723E0F9E-0F1F-4E64-9A6C-8E8652BD9CC9Q60741999-BA8A4546-007C-4076-A677-46A5A33C1A96Q60956969-DBDDC32E-C54F-43F8-88C7-62E46C29B842Q90559471-4AEDC0D5-7E48-47C3-AE27-EC31B93247ACQ91112840-BF32D60C-4A57-4BF8-A853-45C1B3EE390BQ91359141-56EFA5E5-642E-43D6-A4DC-6F7E70E058CAQ91608263-B156AECE-20DE-4F3F-B115-643C07882383Q91807063-A6036126-A67A-4CCB-911C-26A267D630F8Q92069513-78CDE716-AC8C-4A3F-8460-9FC0578C4513Q92132870-94B473F2-4933-4F8A-B0F1-555F85A2D497Q92135219-F7C13572-D2B6-4DF4-A604-11B210216ADFQ92205033-C502D7B6-C03E-457D-ABBA-FECBD5585062Q92380216-141F8567-B2D3-4762-95C8-11690E42898CQ92393850-A556683F-8226-4106-A665-B08AC40EAF33Q92520693-A1CB8DD2-6C8F-4145-83E2-B242077D8FDEQ92639194-38F98EE3-6CF6-49E9-A68C-A4263D230234Q92737110-F4F79CDD-2E69-42BE-8EAF-BC9E25C7BCCFQ95575856-0036E841-F96D-4F63-9B46-B42682CA1B90
P50
description
researcher ORCID ID = 0000-0002-7969-8346
@en
name
Michael Levy
@ast
Michael Levy
@en
Michael Levy
@es
Michael Levy
@nl
type
label
Michael Levy
@ast
Michael Levy
@en
Michael Levy
@es
Michael Levy
@nl
prefLabel
Michael Levy
@ast
Michael Levy
@en
Michael Levy
@es
Michael Levy
@nl
P1153
55687303100
P31
P496
0000-0002-7969-8346